Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan

• Published in: Vaccines (Basel) 2022-02, Vol.10 (2), p.312
• Main Authors: Chang, Jer-Hwa, Chiou, Jeng-Fong, Hung, Ching-Sheng, Liu, Ming-Che, Chang, Hui-Wen, Hong, Shiao-Ya, Wang, Cheng-Yi, Lin, Yi-Ling, Hsieh, Yi-Chen, Chung, Chi-Li, Su, Ying-Shih, Hsiao, Shu-Tai Shen, Liu, Doresses, Liang, Jian-Jong, Liao, Chun-Che, Chang, Chih-Shin, Lai, Kevin Shu-Leung, Chuang, Han-Chuan, Chien, Ko-Ling, Wu, Wei-Ciao, Lee, Yuan-Chii G, Lin, Sey-En, Shen, Yung-Kang, Hsu, Chiung-Fang, Wang, Jude Chu-Chun, Hsiao, Shih-Hsin
• Format: Article
• Language: English
• Subjects: Antibodies; Asian populations; Body weight; ChAdOx1 nCoV-19; Clinical trials; Coronaviruses; COVID-19; COVID-19 vaccines; Dimers; Enzymes; Ethnicity; Fever; Humoral immunity; Immunoassay; Immunogenicity; Immunoglobulin G; Minority & ethnic groups; Pandemics; Platelets; Proteins; Seroconversion; Serology; Severe acute respiratory syndrome coronavirus 2; Vaccination; vaccine; Vaccines
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines10020312

The ChAdOx1 nCoV-19 vaccine has been widely administered against SARS-CoV-2 infection; however, data regarding its immunogenicity, reactogenicity, and potential differences in responses among Asian populations remain scarce. 270 participants without prior COVID-19 were enrolled to receive ChAdOx1 nCoV-19 vaccination with a prime-boost interval of 8-9 weeks. Their specific SARS-CoV-2 antibodies, neutralizing antibody titers (NT50), platelet counts, and D-dimer levels were analyzed before and after vaccination. The seroconversion rates of anti-RBD and anti-spike IgG at day 28 after a boost vaccination (BD28) were 100% and 95.19%, respectively. Anti-RBD and anti-spike IgG levels were highly correlated (r = 0.7891), which were 172.9 ± 170.4 and 179.3 ± 76.88 BAU/mL at BD28, respectively. The geometric mean concentrations (GMCs) of NT50 for all participants increased to 132.9 IU/mL (95% CI 120.0-147.1) at BD28 and were highly correlated with anti-RBD and anti-spike IgG levels (r = 0.8248 and 0.7474, respectively). Body weight index was statistically significantly associated with anti-RBD IgG levels ( = 0.035), while female recipients had higher anti-spike IgG levels ( = 0.038). The GMCs of NT50 declined with age ( = 0.0163) and were significantly different across age groups (159.7 IU/mL for 20-29 years, 99.4 IU/mL for ≥50 years, = 0.0026). Injection-site pain, fever, and fatigue were the major reactogenicity, which were more pronounced after prime vaccination and in younger participants (